LASSI-D™
For Clinicians

Improve patient outcomes with validated NIH supported research

Aging populations make it a global priority to detect the earliest signs of cognitive change. LASSI-D™ is a state-of-the art 15 min. test used for detecting early cognitive changes in people at increased risk for Alzheimer’s disease.

Featured in Research

Outcomes & Impact

Early detection enables better patient outcomes

Accuracy in detecting non-impairment approx.

90%

Accuracy in detecting impairment approx.

80%

High number of test completers

98%

User satisfaction

97%

When cognitive changes are detected early, patients have more treatment options and better long-term outcomes. LASSI-D™ makes early detection easy, affordable, accurate, and actionable.

How LASSI-D™ Works

Providing necessary visibility into cognitive health

LASSI-D™ helps healthcare professionals detect the earliest signs of cognitive and functional change in patients at increased risk for Alzheimer’s disease.

Easy to get started

Works on most computers and tablets

Easy to implement

EMR integration and integrated workflow

Easy to use

Automated scoring and follow-up recommendations

Easy to operate

Continuous training and support

Who We Support

Designed for Real People, Backed by Science

LASSI-D™ is designed to serve people across the spectrum of cognitive health.

People aged 50+

Supporting healthy aging and early detection.

People worried about memory

Peace of mind through proactive screening.

People with mild cognitive impairment

Detecting subtle changes early.

People with chronic medical conditions

Better brain health for those managing complex conditions.

Meet the Minds Behind LASSI-D™

Dr. Rosie E. Curiel, PsyD

Dr. Curiel Cid, is a Neuropsychologist and Professor in the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine and Chief of Cross-Cultural Neuropsychology and Cognitive Neuroscience at the Center for Cognitive Neuroscience and Aging. Dr. Curiel Cid specializes in the early cognitive and functional assessment of neurodegenerative conditions, such as Alzheimers disease and related disorders.

Dr. Rosie E. Curiel, PsyD

View Bio

David Loewenstein, Ph.D.

Dr. David Loewenstein is the Director of the Center for Cognitive Neuroscience and Aging (CNSA). and Professor of Psychiatry and Behavioral Sciences for the University of Miami School of Medicine. He is a board-certified clinical neuropsychologist and Director of the Division of Neuropsychology. Previously, Dr. Loewenstein served as Director of Neuropsychology Laboratories and Research at Mount Sinai Medical Center in Miami Beach, FL and Chief of Psychology for Jackson Memorial Hospital.

David Loewenstein, Ph.D.

View Bio

Dr. Elizabeth Crocco, M.D.

Dr. Elizabeth Crocco is a Clinical Professor and Chief of Geriatric Psychiatry in the Department of Psychiatry and Behavioral Sciences at the University of Miami (UM) Miller School of Medicine in Miami, Florida. She is board certified by the American Board of Psychiatry and Neurology in General Psychiatry with added qualifications in the subspecialty of Geriatric Psychiatry.

Dr. Elizabeth Crocco, M.D.

View Bio

Publications

LASSI-L™: Original paper & pencil based research-focused cognitive challenge test.
LASSI-BC™: Initial research-focused computerized version of the LASSI-L.
LASSI-D™: Brief fully self-administered commercial digital version of the LASSI-L.

What Customers and Assessment Takers are Saying

“I like the AI Avatar guide and that I can take the test on my own and not feel judged by a “real” person.”
Agnes B.
71 y/o
“I like the fact that anyone from my staff can quickly set up the assessment and that it provides automatic scoring and recommendations.”
Dr. John B.
“LASSI-D™ helps me get a more complete picture of my patients cognitive status.”
Dr. Maria T.

Frequently Asked Questions

The recommended use of LASSI-D™ is as a yearly screening test, for individuals over the age of 65 or for individuals older than 50 years with one or more close relatives who had dementia. It can also function as an important value-adding supplement to currently used assessments such as the MoCA or MMSE in adults who have subjective memory complaints but appear cognitively normal. The presence of other risk factors such as certain medical conditions, for example sleep disorders, vascular health conditions, use of certain medications or a history of traumatic brain injury or depression may also warrant the use of the LASSI-D™. The final determination should always be made by the clinician or healthcare provider with direct patient contact.
No special equipment is required, as the LASSI-D™ works on most computers and tablets with a Wi-Fi connection and a good quality microphone. A headset is recommended for better clarity and less distraction.
The assessment takes approx. 15 minutes to administer. The assessment is very easy to set up and administer but customer support in the form of initial training and other support is provided upon request (typically in the form of Team or Zoom meetings) and the LASSI-D™ portal also contains both assessment background and training videos.
Yes, LASSI-D™ has shown equally high discriminant validity in populations that have been underrepresented in Alzheimer’s disease research, namely, Hispanics and African Americans. LASSI-D™ is available in English and Spanish, and more languages are in the process of being added.
No, LASSI-D™ is highly affordable and only priced at a fraction of direct competitors such as blood biomarkers.